COTQF (Cotinga Pharmaceuticals) COGS-to-Revenue : 0.00 (As of Jan. 2020)

View and export this data going back to 2007. Start your Free Trial

What is Cotinga Pharmaceuticals COGS-to-Revenue?

Cotinga Pharmaceuticals's Cost of Goods Sold for the three months ended in Jan. 2020 was $0.00 Mil. Its Revenue for the three months ended in Jan. 2020 was $0.00 Mil.

Cotinga Pharmaceuticals's COGS to Revenue for the three months ended in Jan. 2020 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Cotinga Pharmaceuticals's Gross Margin % for the three months ended in Jan. 2020 was N/A%.

Cotinga Pharmaceuticals COGS-to-Revenue Historical Data

The historical data trend for Cotinga Pharmaceuticals's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cotinga Pharmaceuticals COGS-to-Revenue Chart

Cotinga Pharmaceuticals Annual Data

Trend

Apr10

Apr11

Apr12

Apr13

Apr14

Apr15

Apr16

Apr17

Apr18

Apr19

COGS-to-Revenue

Get a 7-Day Free Trial

Cotinga Pharmaceuticals Quarterly Data
	Apr15	Jul15	Oct15	Jan16	Apr16	Jul16	Oct16	Jan17	Apr17	Jul17	Oct17	Jan18	Apr18	Jul18	Oct18	Jan19	Apr19	Jul19	Oct19	Jan20
COGS-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	-

Cotinga Pharmaceuticals COGS-to-Revenue Calculation

Cotinga Pharmaceuticals's COGS to Revenue for the fiscal year that ended in Apr. 2019 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

Cotinga Pharmaceuticals's COGS to Revenue for the quarter that ended in Jan. 2020 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

Cotinga Pharmaceuticals (OTCPK:COTQF) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Cotinga Pharmaceuticals's Gross Margin % for the three months ended in Jan. 2020 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 0
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Cotinga Pharmaceuticals COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Cotinga Pharmaceuticals's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Cotinga Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cotinga Pharmaceuticals Inc (OTCPK:COTQF) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

82 Richmond Street East, The Canadian Venture Building, Toronto, ON, CAN, M5C1P1

Website

http://www.cotingapharma.com

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

Cotinga Pharmaceuticals Headlines

From GuruFocus

Cotinga Pharmaceuticals Reports Fiscal 2018 Third Quarter Financial and Operating Results

By GlobeNewswire GlobeNewswire • 04-03-2018

Cotinga Pharmacueticals Announces Closing of Unit Offering

By GlobeNewswire GlobeNewswire • 05-22-2019